Contrasting OnKure Therapeutics (OKUR) and Its Peers

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,048 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare OnKure Therapeutics to related businesses based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, profitability, valuation and risk.

Institutional and Insider Ownership

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for OnKure Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7603	20877	48485	1193	2.55

OnKure Therapeutics currently has a consensus price target of $37.50, suggesting a potential upside of 141.16%. As a group, “Pharmaceutical preparations” companies have a potential upside of 72.35%. Given OnKure Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe OnKure Therapeutics is more favorable than its rivals.

Valuation & Earnings

This table compares OnKure Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.27
OnKure Therapeutics Competitors	$2.10 billion	$152.73 million	-5.65

OnKure Therapeutics’ rivals have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

OnKure Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ rivals have a beta of 0.79, suggesting that their average share price is 21% less volatile than the S&P 500.

Profitability

This table compares OnKure Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,620.37%	-274.65%	-33.65%

Summary

OnKure Therapeutics beats its rivals on 9 of the 13 factors compared.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.